Evaluating the Effectiveness of 68Ga-grazytracer PET/CT in Inflammatory Bowel Disease

NANot yet recruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Inflammatory Bowel Diseases (IBD)
Interventions
DIAGNOSTIC_TEST

68Ga-grazytracer PET/CT Scan

The imaging agent 68Ga-grazytracer used in this project is synthesised in accordance with the standards for the production of radiopharmaceuticals with reference to the Chinese Pharmacopoeia (18F-FDG quality standard). pH value is between 5.0-8.0; radiochemical purity is not less than 95%, and the content of bacterial endotoxin per mL of solution is less than 15EU; the concentration of radioactivity is not less than 37MBq/mL; the solvent The residual amount of solvent complies with the regulations. Specification: 185\~1850 MBq/ml Characteristics Colourless and transparent, no visible particles. Physical half-life: 68 minutes for 68Ga. Stable for 3 half-lives from the time of labelling. Method of administration: Intravenous. Dose: 0.05Ci/kg, followed by a 5 mL saline flush.

Trial Locations (1)

Unknown

Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical University, Xi'an, China, Xi'an, Shaanxi Province, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER

NCT07022080 - Evaluating the Effectiveness of 68Ga-grazytracer PET/CT in Inflammatory Bowel Disease | Biotech Hunter | Biotech Hunter